Novo Nordisk A/S (NVO) vs Regencell Bioscience Holdings Limited (RGC)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| NVO | RGC | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - Specialty & Generic |
| Size band | LARGE | MID |
| Listing | NYSE | Nasdaq CM |
| Country | Denmark | Hong Kong |
| Theme | glp-1-and-obesity | neuroscience |
| Price and returns | ||
| Last close | $39.13 | $6.76 |
| Return · 1 week | +1.85% | −32.74% |
| Return · 1 month | +1.08% | +9.03% |
| Return · 3 months | −23.21% | +13.23% |
| Return · year to date | −22.57% | −67.09% |
| Return · 1 year | −23.30% | −59.06% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −39.01% | −90.20% |
| 52-week high | $64.16 | $69.00 |
| 52-week low | $35.12 | $4.51 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $172.64B | $3.35B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $405.29M | $900.09K |
| Employees | 66,700 | 10 |
| Valuation | ||
| Price to earnings · trailing | 9.14× | n/a (negative earnings) |
| Price to earnings · forward | 11.33× | — |
| Price to sales | 0.52× | — |
| Price to book | 5.19× | 355.19× |
| Enterprise value to EBITDA | 1.54× | n/a (negative value) |
| Enterprise value to revenue | 0.81× | — |
| PEG ratio | 4.35 | — |
| Earnings per share · trailing | 4.25 | -0.02 |
| Profitability | ||
| Gross margin | 80.65% | — |
| Operating margin | 42.54% | 0.00% |
| Profit margin | 35.35% | — |
| Return on equity | 59.82% | −128.53% |
| Return on assets | 18.73% | −71.54% |
| Growth | ||
| Revenue growth | +2.10% | — |
| Earnings growth | −20.60% | — |
| Balance sheet and payout | ||
| Debt / equity (%) | 63.33 | 2.22 |
| Current ratio | 0.87 | 10.77 |
| Dividend yield | 4.63% | 0.00% |
| Payout ratio | 43.10% | — |
| Trend and volatility | ||
| RSI · 14 | 46.28 | 68.21 |
| ADX · 14 | 20.53 | 54.54 |
| 50-day average | $41.77 | $6.63 |
| 200-day average | $44.60 | $18.19 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 1.91% | 19.12% |
The full NVO analysis
Everything this table leaves out for Novo Nordisk A/S: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the NVO argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full NVO analysisThe full RGC analysis
Everything this table leaves out for Regencell Bioscience Holdings Limited: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the RGC argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full RGC analysis